Desmoid: The Role of Local Therapy In an Era of Systemic Options

Opinion statement Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment mod...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current treatment options in oncology 2013-09, Vol.14 (3), p.465-473
Hauptverfasser: Walczak, Brian E., Rose, Peter S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 473
container_issue 3
container_start_page 465
container_title Current treatment options in oncology
container_volume 14
creator Walczak, Brian E.
Rose, Peter S.
description Opinion statement Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.
doi_str_mv 10.1007/s11864-013-0235-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1431296255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3065753071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</originalsourceid><addsrcrecordid>eNp1kM9LwzAUx4Mobk7_AC9S8OKlmh9N0nhS5tTBYKDzHJI01Y62qUl72H9vS6eI4OmF9z7v-8IHgHMErxGE_CYglLIkhojEEBMa8wMwRZQkMcOcHw5vzGPMsZiAkxC2EGKaQHEMJphwBgUSU3D3YEPliuw22nzY6MWVNnJ5tHJGlUPHq2YXLetI1dHCq2H0ugutrQoTrZu2cHU4BUe5KoM929cZeHtcbObP8Wr9tJzfr2JDOG5jSommggmKUgM15JngjHCaYEWYhdpoIRjUlGYi5TwhBFmjMpTrXHGtRSrIDFyNuY13n50NrayKYGxZqtq6LkiUEIQFw_2hGbj8g25d5-v-dwMFOUx7ez2FRsp4F4K3uWx8USm_kwjKQa8c9cperxz0St7vXOyTO13Z7Gfj22cP4BEI_ah-t_7X6X9TvwCC-oFh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1430708100</pqid></control><display><type>article</type><title>Desmoid: The Role of Local Therapy In an Era of Systemic Options</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Walczak, Brian E. ; Rose, Peter S.</creator><creatorcontrib>Walczak, Brian E. ; Rose, Peter S.</creatorcontrib><description>Opinion statement Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-013-0235-7</identifier><identifier>PMID: 23760919</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>beta Catenin - genetics ; Combined Modality Therapy ; Drug Therapy ; Fibromatosis, Aggressive - diagnosis ; Fibromatosis, Aggressive - drug therapy ; Fibromatosis, Aggressive - genetics ; Fibromatosis, Aggressive - pathology ; Fibromatosis, Aggressive - surgery ; Humans ; Maf Transcription Factors - genetics ; Maf Transcription Factors - metabolism ; Medicine ; Medicine &amp; Public Health ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; Oncology ; Sarcoma (SH Okuno ; Section Editor</subject><ispartof>Current treatment options in oncology, 2013-09, Vol.14 (3), p.465-473</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</citedby><cites>FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-013-0235-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-013-0235-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23760919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walczak, Brian E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><title>Desmoid: The Role of Local Therapy In an Era of Systemic Options</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.</description><subject>beta Catenin - genetics</subject><subject>Combined Modality Therapy</subject><subject>Drug Therapy</subject><subject>Fibromatosis, Aggressive - diagnosis</subject><subject>Fibromatosis, Aggressive - drug therapy</subject><subject>Fibromatosis, Aggressive - genetics</subject><subject>Fibromatosis, Aggressive - pathology</subject><subject>Fibromatosis, Aggressive - surgery</subject><subject>Humans</subject><subject>Maf Transcription Factors - genetics</subject><subject>Maf Transcription Factors - metabolism</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Oncology</subject><subject>Sarcoma (SH Okuno</subject><subject>Section Editor</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kM9LwzAUx4Mobk7_AC9S8OKlmh9N0nhS5tTBYKDzHJI01Y62qUl72H9vS6eI4OmF9z7v-8IHgHMErxGE_CYglLIkhojEEBMa8wMwRZQkMcOcHw5vzGPMsZiAkxC2EGKaQHEMJphwBgUSU3D3YEPliuw22nzY6MWVNnJ5tHJGlUPHq2YXLetI1dHCq2H0ugutrQoTrZu2cHU4BUe5KoM929cZeHtcbObP8Wr9tJzfr2JDOG5jSommggmKUgM15JngjHCaYEWYhdpoIRjUlGYi5TwhBFmjMpTrXHGtRSrIDFyNuY13n50NrayKYGxZqtq6LkiUEIQFw_2hGbj8g25d5-v-dwMFOUx7ez2FRsp4F4K3uWx8USm_kwjKQa8c9cperxz0St7vXOyTO13Z7Gfj22cP4BEI_ah-t_7X6X9TvwCC-oFh</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Walczak, Brian E.</creator><creator>Rose, Peter S.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130901</creationdate><title>Desmoid: The Role of Local Therapy In an Era of Systemic Options</title><author>Walczak, Brian E. ; Rose, Peter S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-553b5969518c0b07d97637542a36e0bcb9960b55d98774331ecad1fbfa7bb9893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>beta Catenin - genetics</topic><topic>Combined Modality Therapy</topic><topic>Drug Therapy</topic><topic>Fibromatosis, Aggressive - diagnosis</topic><topic>Fibromatosis, Aggressive - drug therapy</topic><topic>Fibromatosis, Aggressive - genetics</topic><topic>Fibromatosis, Aggressive - pathology</topic><topic>Fibromatosis, Aggressive - surgery</topic><topic>Humans</topic><topic>Maf Transcription Factors - genetics</topic><topic>Maf Transcription Factors - metabolism</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Oncology</topic><topic>Sarcoma (SH Okuno</topic><topic>Section Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walczak, Brian E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walczak, Brian E.</au><au>Rose, Peter S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Desmoid: The Role of Local Therapy In an Era of Systemic Options</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>14</volume><issue>3</issue><spage>465</spage><epage>473</epage><pages>465-473</pages><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement Extra-abdominal desmoid tumors continue to present unique challenges. Although the majority of patients can achieve durable local control, recalcitrant disease can prove frustrating for patients, their families, and providers. This is especially true when morbid local treatment modalities are undertaken in hopes of controlling a benign disease. There is little universal agreement regarding the optimal management of this potentially locally aggressive neoplasm; however, the overall goal of treatment is durable local control. Because of the unpredictable nature of desmoid tumors, treatment must be individualized on a case-by-case basis, utilizing a multimodal approach, and optimized in a multidisciplinary setting. Primary desmoid tumors that are symptomatic or progressing and can be excised with function-sparing surgery are treated operatively; surgical excision with negative margins (R0 resection) is generally the preferred method of treatment. Radiation therapy is used in combination with surgical resection for microscopically positive margins (R1 resection) when future recurrence may jeopardize limb preservation or function. For symptomatic or enlarging desmoids where surgery will incur significant functional deficits in order to obtain at best an R1 resection, definitive radiation or percutaneous ablation is utilized. Desmoid tumors that are asymptomatic, not enlarging, and located in areas that are remote from vital structures may be carefully observed. Systemic therapy is commonly utilized as an adjunct or primary treatment for symptomatic or enlarging tumors. The mainstay of treatment of recurrent desmoids tumor is surgery with a goal of an R0 resection often combined with radiation therapy. The evolving role of alternative methods of local control (such as cryoablation) is currently being investigated. As the cellular understanding of desmoid tumor improves, the ability to better predict the biological behavior will hopefully improve treatment selection.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23760919</pmid><doi>10.1007/s11864-013-0235-7</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1527-2729
ispartof Current treatment options in oncology, 2013-09, Vol.14 (3), p.465-473
issn 1527-2729
1534-6277
1534-5277
language eng
recordid cdi_proquest_miscellaneous_1431296255
source MEDLINE; SpringerLink Journals
subjects beta Catenin - genetics
Combined Modality Therapy
Drug Therapy
Fibromatosis, Aggressive - diagnosis
Fibromatosis, Aggressive - drug therapy
Fibromatosis, Aggressive - genetics
Fibromatosis, Aggressive - pathology
Fibromatosis, Aggressive - surgery
Humans
Maf Transcription Factors - genetics
Maf Transcription Factors - metabolism
Medicine
Medicine & Public Health
Neoplasm Recurrence, Local - diagnosis
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - surgery
Oncology
Sarcoma (SH Okuno
Section Editor
title Desmoid: The Role of Local Therapy In an Era of Systemic Options
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A02%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Desmoid:%20The%20Role%20of%20Local%20Therapy%20In%20an%20Era%20of%20Systemic%20Options&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Walczak,%20Brian%20E.&rft.date=2013-09-01&rft.volume=14&rft.issue=3&rft.spage=465&rft.epage=473&rft.pages=465-473&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-013-0235-7&rft_dat=%3Cproquest_cross%3E3065753071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1430708100&rft_id=info:pmid/23760919&rfr_iscdi=true